

## FACTSHEET: Coalition to Accelerate Access to Long-Acting PrEP

February 2024

### Coalition Co-Convenors:



### Coalition Secretariat:



### Purpose

The Coalition to Accelerate Access to Long-Acting PrEP brings together donors, civil society, ministries of health, implementation science think tanks and partner organizations to ensure an accelerated, equitable, sustainable, and collaborative approach to optimizing access to new long-acting PrEP options. The Coalition is convened by the Global Fund, PEPFAR, Unitaid, UNAIDS and WHO, with AVAC as the Secretariat.

The Coalition's objective is practical: ***to coordinate key stakeholder activities on long-acting PrEP access, including jointly developing strategies to identify and overcome access challenges for new PrEP options available now and those in the pipeline.***

The Coalition is committed to transparency and will disseminate a quarterly update to chart progress overall and will periodically update the [Plan for Accelerating Access and Introduction of Injectable CAB for PrEP](#) with timelines and milestones across the full range of PrEP options. For more information and/or with questions for the Coalition co-convenors, contact [LAPrEPcoalition@avac.org](mailto:LAPrEPcoalition@avac.org).

### Rationale

The **Coalition to Accelerate Access to Long-Acting PrEP** will urgently apply lessons learned from oral PrEP, create plans to overcome the unique challenges for new prevention options, with the aim that new, longer-acting PrEP options will be quickly and equitably accessible to all who need them, focused especially on low- and middle-income countries (LMICs).


More than 10 years ago, research showed oral PrEP was safe and effective in preventing HIV. In 2012, it was approved for use by the US Food and Drug Administration and subsequently recommended for all people at substantial risk of HIV by the World Health Organization (WHO). But the global health community moved too slowly and more than a decade later, only 5.67 million people have initiated oral PrEP use (cumulative number of initiations from 2012 to September 2023), a fraction of the estimated number of people who need it and could benefit from it. With new, longer-acting PrEP options reaching the market, the global health field needs to bring bold actions, global urgency, and coordinated partnerships to meet the challenges of product access, roll-out, and use. Product developers, policy makers, normative agencies, donors, program implementers, researchers, manufacturers, civil society, advocates, and communities all have critical roles

to play. Strategic action is needed to ensure that science is translated into public health impact without unnecessary delay.

## Structure

The Coalition will work through structures and systems designed to facilitate critical work in specific technical areas while ensuring that these work streams are coordinated, linked to other key efforts driving access to PrEP and prevention generally, and capitalize on opportunities to advocate for and strengthen delivery of new PrEP products.

1. **Coalition:** The Coalition includes the Convenors, Donor Caucus, Civil Society Caucus, MoH representatives, MPP, and BioPIC stakeholders.
2. **Co-Convenors:** The Coalition is co-convened by the Global Fund, PEPFAR, UNAIDS, Unitaid, WHO. The convenors are responsible for championing the Coalition’s overall effort to ensure its internal cohesion and external visibility.
3. **Secretariat/Communications:** AVAC serves as Secretariat and Communications lead, coordinating the Coalition and communications, internally among entities in the Coalition and externally to key constituencies. As Secretariat, AVAC will support the Coalition including all Coalition stakeholders and any working groups by drafting documents; scheduling calls; producing and distributing call notes and action items; ensuring coordination among the working groups and other tasks as needed. AVAC will establish and maintain an online platform for sharing documents and maintain and update this platform. To ensure transparency, the Secretariat will also be responsible for developing a communications strategy and consolidating and disseminating quarterly updates on key developments related to long-acting PrEP delivery.



## Stakeholders

The global effort to ensure swift rollout of longer-acting PrEP extends beyond the Coalition. To ensure greatest impact, the Coalition will strategically collaborate with the following non-exhaustive list of stakeholders.

Stakeholder type	Description
Donor Caucus	Established in 2019, the donor group is coordinated by USAID and the Bill & Melinda Gates Foundation. This donor-only forum is a platform for confidential conversations among donors to ensure alignment on longer-acting PrEP investments.
Civil Society Caucus	Established in 2022 to ensure civil society expertise influences the rollout of long-acting PrEP options. This Caucus includes representation from many civil society groups working on longer-acting PrEP introduction. These include, but are not exclusive to, the following:- African Women Community Prevention Accountability Board; AfroCAB; APCOM; AVAC; Coalition to Accelerate and Support Prevention Research (CASPR); Global Black Gay Men Connect (GBGMC); the Global Key Population Advisory Group. The group meets bi-monthly for updates on long-acting PrEP activities, direct engagement with key stakeholders and shared strategy development. Caucus members are also expected to provide updates to the groups and coalitions they represent.
Biomedical Prevention Implementation Collaborative (BioPIC)	Funded by the Bill & Melinda Gates Foundation and implemented by AVAC, BioPIC collaborates with WHO to convene bi-monthly think tanks for implementation science projects and new PrEP introduction programs to link them in generating key insights for people-centered product delivery. BioPIC also developed the <a href="#">Adaptable Product Introduction Framework</a> for all stakeholders involved in product introduction, from clinical research to rollout in low- and middle-income countries.
HIV Modeling Consortium	Members of the Consortium met in March 2023 and identified a need to link more directly with implementation science projects that are gathering actual data that can be fed into models used to guide decision-making. The Coalition Conveners and BioPIC are working with the Modeling Consortium to ensure these links are embedded in planning activities.
Medical Patent Pool (MPP)	The Coalition collaborates with the MPP on generic licensing efforts.
Additional Caucuses	Other caucuses may represent interest groups and perspectives critical to shaping the Coalition and its work and will be designed to ensure that these views infuse the Coalition’s efforts at all levels. The Coalition may convene specific groups as needed.
Global HIV Prevention Coalition (GPC)	Established in 2017 with UNAIDS and UNFPA as co-conveners, the GPC currently brings together 38 United Nations Member States, focus countries, donor countries, international and regional organizations, CS organizations and networks to strengthen and sustain political commitment for primary prevention by setting a common agenda among key policymakers, funders, and program implementers. This Coalition coordinates with GPC and ensures that bidirectional communications and information-sharing between the coalitions are collaborative and consistent and allow for efficient and effective coordination.